Health Care Related Organization
Ascletis’ Oral GLP-1 Drug Shows Promising Early Results in Obesity Treatment, Rivaling Roche’s Candidate
Ascletis Pharma, obesity treatment, oral GLP-1 receptor agonist, ASC30, weight loss, clinical trials, Roche, CT-996, pharmaceutical competition
Major Budget Cuts and Layoffs Hit US Health Agencies: Impacts on CDC, NIH, and Public Health
healthcare budget cuts, CDC layoffs, NIH funding reduction, public health impact, Trump administration, federal workforce reduction, medical research funding
GSK’s Penmenvy Gains FDA Approval, Joining Pfizer in 5-in-1 Meningococcal Vaccine Market
Penmenvy, GSK, FDA approval, meningococcal vaccine, 5-in-1 vaccine, Pfizer, Penbraya, invasive meningococcal disease (IMD), adolescents and young adults
Massive Layoffs Sweep Federal Health Agencies: Thousands of Workers Impacted Across HHS
HHS layoffs, federal health agencies, probationary workers, Trump administration, workforce reduction, CDC, NIH, FDA, CMS
Mass Layoffs at HHS: Trump Administration Cuts Thousands of Probationary Workers
HHS layoffs, probationary employees, Trump administration, CDC, NIH, FDA, federal workforce reduction, public health impact
Bristol Myers Squibb’s Opdualag Fails Phase 3 Trial in Adjuvant Melanoma Treatment
Opdualag, Bristol Myers Squibb, melanoma, clinical trial failure, LAG-3 inhibitor, immunotherapy, adjuvant treatment
AI-Driven Enzyme Engineering: Baker Lab’s Latest Breakthrough in Computational Protein Design
AI-generated enzymes, computational protein design, artificial luciferases, de novo enzyme engineering, machine learning in biochemistry, Baker Lab, University of Washington
Leadership Changes at Agios and Moderna: Board Resignation and New Marketing Chief
David Schenkein, Agios Pharmaceuticals, board resignation, Moderna, Amy Mahery, chief marketing officer, pharmaceutical industry, leadership changes
FDA Approves Pfizer’s Adcetris Combination Therapy for Relapsed/Refractory Large B-cell Lymphoma
Adcetris, brentuximab vedotin, FDA approval, large B-cell lymphoma, LBCL, DLBCL, antibody-drug conjugate, Pfizer, combination therapy
Newleos Therapeutics Launches with $93.5M to Advance Novel Neuropsychiatric Treatments
Newleos Therapeutics, mental health, neuropsychiatry, Roche assets, Series A funding, anxiety disorders, substance use disorders, GABA modulators